Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2527082 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL7407458 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL19141 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL719374 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL7408161 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL989611 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL9353850 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL642929 | 0.98 | TSHR (0.67) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL48697 | 0.93 | TSHR (0.75) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL3502791 | 0.87 | TSHR (0.82) | TSHRALDH1A1LMNAKMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117769559-A | TRAP1 inhibitors and uses thereof | 斯玛特恩生物公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20190134206-A1 | CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION | ALNYLAM PHARMACEUTICALS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20150196655-A1 | CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2015-07-16 | — | — | US | disclosed |
| US-20150196655-A1 | CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2015-07-16 | — | — | US | disclosed |
| WO-2014025805-A1 | CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-7482376-B2 | Conjugated complement cascade inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1644046-A2 | CONJUGATED COMPLEMENT CASCADE INHIBITORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005002627-A2 | CONJUGATED COMPLEMENT CASCADE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004031-A1 | Conjugated complement cascade inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-5650430-A | Radicicol derivatives, their preparation and their anti-tumor activity | SANKYO COMPANY, LIMITED (JP) | 1997-07-22 | — | — | US | disclosed |
| CN-1035381-C | Radicicol derivatives, their preparation and their anti-tumor activity | SANKYO CO (JP) | 1997-07-09 | — | — | CN | disclosed |
| US-5597846-A | ESTERS OF RADICICOL | SANKYO COMPANY, LIMITED (JP) | 1997-01-28 | — | — | US | disclosed |
| CN-1059720-A | Radicicol derivatives, its preparation method and anti-tumor activity thereof | SANKYO CO (JP) | 1992-03-25 | — | — | CN | disclosed |
| WO-1991018905-A1 | RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY | SANKYO COMPANY LIMITED (JP) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134206-A1 | CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION | RNASE1, IGF2BP1, IGF2BP2 | TSHR 2308/4885ALDH1A1 2059/4885LMNA 700/4885 |
| US-20050004031-A1 | Conjugated complement cascade inhibitors | C9, CFH, CFB | TSHR 2818/4885ALDH1A1 3147/4885LMNA 2162/4885 |
| US-20150196655-A1 | CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION | RNASE1, IGF2BP1, IGF2BP2 | TSHR 2308/4885ALDH1A1 2059/4885LMNA 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.